The role of Uro-Vaxom in reducing infectious adverse effects and improving outcomes in bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.

Investig Clin Urol · 2025 · PMC12277912 · PMID 40618210

Europe PMC DOI

hedged sentence

0.2120

closest p · 4.2× alpha

0.2120

boldest claim

The sentences

did not reach statistical significancep=0.212not close (p > 0.1)

Although tumor recurrence rates within one year were lower in the UVX group, this difference did not reach statistical significance (p=0.212).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.